In 2009, members of the Pharmaceutical Research and Manufacturers of America (PhRMA) spent an estimated $45,782 million on R&D, a 3.4% decline. R&D spending by the total biopharmaceutical industry is estimated to have increased 2.5% to $65.3 billion. PhRMA members’ domestic R&D spending declined 2.2% to $34,806 million, while their foreign R&D spending fell 7.1% to $10,976 million. As a percentage of sales, domestic R&D was 19.0% and foreign R&D was 16.0%. In 2008, licensed-in R&D accounted for 18.5% of domestic R&D spending by PhRMA members. Also in 2008, Prehuman/Preclinical, Phase I, Phase II, Phase III, Approval and Phase IV accounted for 27.0%, 8.2%, 12.9%, 32.5%, 4.7% and 14.4% of R&D spending, respectively. PhRMA members’ biologics/biotech R&D spending in 2008 totaled $13,685 million, or 28.8% of R&D expenditures. R&D personnel at PhRMA members in 2008 consisted of 80,654 R&D staff and 10,067 supported non-R&D staff. R&D staff percentage by function was: 28.8% for prehuman/preclincal, 7.1% for Phase I, 10.5% for Phase II, 23.5% for Phase III, 5.5% for Approval and 12.9% for Phase IV.

Source: PhRMA